Preclinical Investigations Toward Gd-free Molecularly Targeted Dual-Modal, MRI Dynamic (DCE-MRI)/Optical Imaging Contrast Agent for Cardiac Angiosarcoma

Preclinical MRI imaging justified the efficacy of Mn(II)L1. L1 validated as a promising visible and NIR1dye along with its ability to bind and inhibit pan-cancer targets, FAP (allosteric) and EGFR kinases. Previously validated features of lifetime sensing/high stokes shift and Cu (II) quenching are also noteworthy. Dual-echo acquisitions for quantitative DCE-MRI as a standalone (with T2* corrections) or in combination with PET/MRI of 64Cu-L1(separately studied) or as 52MnL1 by single injection envisaged. T1 mapping for therapy response monitoring based on the reduction of native tumor T1 upon binding of MnL1 to the kinase is hereby envisaged for the future.